Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Rosni Adinin"'
Autor:
Michael J. Overman, Rosni Adinin, Cathy Eng, James L. Abbruzzese, Gauri R. Varadhachary, Jeffrey S. Morris, Scott Kopetz, Robert A. Wolff, E. Lin
Publikováno v:
Journal of Clinical Oncology. 27:2598-2603
Purpose Adenocarcinomas of the small bowel and ampulla of Vater represent rare cancers that have limited data regarding first-line therapy. We conducted a phase II trial to evaluate the benefit of capecitabine in combination with oxaliplatin (CAPOX)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44cdfe36266cb1065983e4d2f133ba02
https://doi.org/10.1200/jco.2008.19.7145
https://doi.org/10.1200/jco.2008.19.7145
Autor:
Ronald S. Walters, Rosni Adinin, James L. Wade, Lajos Pusztai, Vicente Valero, Karen Hoelzer, Banu Arun, Gabriel N. Hortobagyi, Edgardo Rivera, Melanie E. Royce
Publikováno v:
Journal of Clinical Oncology. 21:3249-3254
Purpose: We conducted a phase II clinical trial to determine the clinical efficacy and safety of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. Patients and Methods: Patients were eligible i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58183c9d3b148ac18de44a57a59b992d
https://doi.org/10.1200/jco.2003.03.111
https://doi.org/10.1200/jco.2003.03.111
Autor:
Leslie Wood, N. Yamagata, Alexandria T. Phan, K. Matsuno, Alain C. Mita, Rosni Adinin, S. Bullock, K. K. Sankhala, Muralidhar Beeram, T. Fujisawa
Publikováno v:
Journal of Clinical Oncology. 27:2535-2535
2535 Background: MBP-426 is a novel liposome encapsulated oxaliplatin (L-OHP) formulation bound to human transferrin, developed to improve the safety and efficacy of L -OHP through the prolongation of circulation time and by targeting transferrin rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67375c335ff7d7db80a40f0d3d0fc8c6
https://doi.org/10.1200/jco.2009.27.15_suppl.2535
https://doi.org/10.1200/jco.2009.27.15_suppl.2535
Autor:
Alain C. Mita, C. H. Takimoto, J. Rodon, Scott Kopetz, T. Toko, K. Arakawa, K. Burns, Rosni Adinin, K. K. Sankhala, H. Q. Xiong
Publikováno v:
Journal of Clinical Oncology. 26:2577-2577
2577 Background: TAS-109 is a novel deoxycitidine analogue with unique mechanism of action. Brief exposure to high concentrations of TAS-109 inhibits DNA polymerase resulting in S-phase arrest, while prolonged exposure to TAS-109 at low concentration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a7e2abbbbe20a6989f6d71fd9f12f29
https://doi.org/10.1200/jco.2008.26.15_suppl.2577
https://doi.org/10.1200/jco.2008.26.15_suppl.2577
Autor:
A. Mita, Gabriel N. Hortobagyi, Marjorie C. Green, Richard L. Theriault, N. Bindra, M. Hofweber, M. Fukushima, Rosni Adinin, Lajos Pusztai
Publikováno v:
Journal of Clinical Oncology. 24:10576-10576
10576 Background: TAS-102 is an oral combination of 5-trifluorothymidine (FTD) and a thymidine phosphorylase (TP) inhibitor. FTD is an antineoplastic antimetabolite that causes DNA-fragmentation after passive incorporation into DNA. The TP inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::119b38f8cb45d2bb9d02b49af1206e7d
https://doi.org/10.1200/jco.2006.24.18_suppl.10576
https://doi.org/10.1200/jco.2006.24.18_suppl.10576